Jiang Wenbin
Company insiders · PRESIDENT AND CEO · Director · Cytek Biosciences, Inc.
- Reported transaction lines
- 12
- Buy lines
- 0
- Sell lines
- 0
Filing activity by month
Original filing lines in up to 12 months with activity.
- 2026-1112
Frequently disclosed stocks
Disclosure history
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source |
|---|---|---|---|---|---|---|
| Jiang Wenbin PRESIDENT AND CEO · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 762842 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter. | 2026-11-18 | 2026-11-20 | 57,212 shares/units | SEC 4 |
| Jiang Wenbin PRESIDENT AND CEO · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 270692 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter. | 2026-11-18 | 2026-11-20 | 29,002 shares/units | SEC 4 |
| Jiang Wenbin PRESIDENT AND CEO · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 117873 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. | 2026-11-18 | 2026-11-20 | 22,100 shares/units | SEC 4 |
| Jiang Wenbin PRESIDENT AND CEO · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 15713 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. · The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter. | 2026-11-18 | 2026-11-20 | 11,781 shares/units | SEC 4 |
| Jiang Wenbin PRESIDENT AND CEO · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Other transactionFiling detailsSEC transaction code F Common Stock · Direct ownership · Reported balance after transaction: 5633865 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. | 2026-11-18 | 2026-11-20 | 22,513 shares/units | SEC 4 |
| Jiang Wenbin PRESIDENT AND CEO · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 5656378 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. | 2026-11-18 | 2026-11-20 | 57,212 shares/units | SEC 4 |
| Jiang Wenbin PRESIDENT AND CEO · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Other transactionFiling detailsSEC transaction code F Common Stock · Direct ownership · Reported balance after transaction: 5599166 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. | 2026-11-18 | 2026-11-20 | 11,413 shares/units | SEC 4 |
| Jiang Wenbin PRESIDENT AND CEO · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 5610579 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. | 2026-11-18 | 2026-11-20 | 29,002 shares/units | SEC 4 |
| Jiang Wenbin PRESIDENT AND CEO · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Other transactionFiling detailsSEC transaction code F Common Stock · Direct ownership · Reported balance after transaction: 5581577 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. | 2026-11-18 | 2026-11-20 | 8,697 shares/units | SEC 4 |
| Jiang Wenbin PRESIDENT AND CEO · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 5590274 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. | 2026-11-18 | 2026-11-20 | 22,100 shares/units | SEC 4 |
| Jiang Wenbin PRESIDENT AND CEO · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Other transactionFiling detailsSEC transaction code F Common Stock · Direct ownership · Reported balance after transaction: 5568174 · Securities delivered or withheld for tax or exercise payment · Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. | 2026-11-18 | 2026-11-20 | 4,636 shares/units | SEC 4 |
| Jiang Wenbin PRESIDENT AND CEO · Director · Cytek Biosciences, Inc. | CTKB Cytek Biosciences, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 5572810 · Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. | 2026-11-18 | 2026-11-20 | 11,781 shares/units | SEC 4 |
Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.